Opko Health Inc (OPK) : Traders are bullish on Opko Health Inc (OPK) as it has outperformed the S&P 500 by a wide margin of 6.01% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.72% in the last 1 week, and is up 3.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 6.53% and the 50-Day Moving Average is 4.14%.The 200 Day SMA reached 4.4% Opko Health, Inc. is up 12.82% in the last 3-month period. Year-to-Date the stock performance stands at 1.59%.
Opko Health Inc (OPK) : The highest level Opko Health Inc (OPK) is projected to reach is $20 for the short term and the lowest estimate is at $10. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $15.33 and the possibility the share price can swing is $5.03.
For the current week, the company shares have a recommendation consensus of Buy. Opko Health Inc (NYSE:OPK): stock was range-bound between the intraday low of $10.15 and the intraday high of $10.32 after having opened at $10.16 on Fridays session. The stock finally closed in the red at $10.16, a loss of -0.10%. The stock remained in the red for the whole trading day. The total traded volume was 3,875,120 shares. The stock failed to cross $10.32 in Fridays trading. The stocks closing price on Thursday was $10.21.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.